RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Hold" by Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been assigned an average recommendation of "Hold" from the ten analysts that are covering the company, MarketBeat.com reports. Nine investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $18.17.

RAPT has been the subject of a number of recent research reports. UBS Group dropped their price objective on RAPT Therapeutics from $10.00 to $2.00 and set a "neutral" rating for the company in a research report on Monday, September 9th. HC Wainwright reissued a "neutral" rating on shares of RAPT Therapeutics in a research note on Tuesday, August 20th.

RAPT Therapeutics Stock Performance

RAPT Therapeutics stock traded down $0.15 during midday trading on Monday, reaching $1.65. 222,094 shares of the company were exchanged, compared to its average volume of 735,461. The company has a market capitalization of $57.42 million, a price-to-earnings ratio of -0.56 and a beta of 0.33. The firm's 50-day simple moving average is $2.02 and its 200-day simple moving average is $3.79. RAPT Therapeutics has a 1 year low of $1.64 and a 1 year high of $27.35.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.71) EPS for the quarter, topping analysts' consensus estimates of ($0.74) by $0.03. On average, analysts forecast that RAPT Therapeutics will post -2.73 EPS for the current fiscal year.

Hedge Funds Weigh In On RAPT Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in shares of RAPT Therapeutics by 21.2% in the 1st quarter. Vanguard Group Inc. now owns 2,492,850 shares of the company's stock valued at $22,386,000 after purchasing an additional 436,629 shares in the last quarter. Kingdon Capital Management L.L.C. lifted its stake in shares of RAPT Therapeutics by 55.3% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 1,500,000 shares of the company's stock valued at $13,470,000 after purchasing an additional 534,172 shares in the last quarter. Federated Hermes Inc. lifted its stake in shares of RAPT Therapeutics by 188.7% in the 2nd quarter. Federated Hermes Inc. now owns 796,080 shares of the company's stock valued at $2,428,000 after purchasing an additional 520,368 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in shares of RAPT Therapeutics by 176,725.0% in the 2nd quarter. Point72 Asset Management L.P. now owns 707,300 shares of the company's stock valued at $2,157,000 after purchasing an additional 706,900 shares in the last quarter. Finally, Redmile Group LLC lifted its stake in shares of RAPT Therapeutics by 80.6% in the 1st quarter. Redmile Group LLC now owns 662,398 shares of the company's stock valued at $5,948,000 after purchasing an additional 295,622 shares in the last quarter. 99.09% of the stock is owned by institutional investors and hedge funds.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.